[go: up one dir, main page]

CN105820058A - 精氨酸脱亚氨酶4的新型抑制剂 - Google Patents

精氨酸脱亚氨酶4的新型抑制剂 Download PDF

Info

Publication number
CN105820058A
CN105820058A CN201610116096.7A CN201610116096A CN105820058A CN 105820058 A CN105820058 A CN 105820058A CN 201610116096 A CN201610116096 A CN 201610116096A CN 105820058 A CN105820058 A CN 105820058A
Authority
CN
China
Prior art keywords
pad4
compound
protein
nsc299189
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610116096.7A
Other languages
English (en)
Inventor
林建平
李冬梅
魏宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nankai University
Original Assignee
Nankai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nankai University filed Critical Nankai University
Priority to CN201610116096.7A priority Critical patent/CN105820058A/zh
Publication of CN105820058A publication Critical patent/CN105820058A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/28—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of non-condensed quinone rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03015—Protein-arginine deiminase (3.5.3.15)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供了1种精氨酸脱亚氨酶4(PAD4)的新型抑制剂，该化合物与PAD4之间的解离常数KD值为112μM。

Description

精氨酸脱亚氨酶4的新型抑制剂
技术领域
本发明属于药物化合物领域，更具体地，涉及精氨酸脱亚氨酶4(PAD4)的抑制剂及其结合PAD4的应用。
背景技术
类风湿性关节炎(rheumatoidarthritis，RA)是一种严重的威胁人类健康的慢性自身免疫性疾病。目前治疗RA的方法是缓解症状，如抗炎、消肿和止痛等。非甾体抗炎药(NSAIDs)作为一线抗RA药，减少组织疼痛和炎症，包括阿司匹林、塞来昔布、美洛昔康和可的松(糖皮质激素)等。NSAIDs药物能减轻临床症状但不能根治炎症，无法阻止关节破坏、组织损伤等，需要与其他抗风湿药物联合使用才能有效控制病情。改善病情抗风湿药(DMARDs)作为二线抗RA药，用于缓解或阻止RA软骨和关节的损伤，包括甲氨蝶呤、羟化氯喹等。DMARDs类药物通常起效慢，影响RA患者的自身机体免疫过程。目前的治疗药物对RA的免疫病理机制无决定性影响，不能从根本上治疗治疗RA，因此发展针对RA发病机理的药物是必要的。
近年来发现，PAD4是治疗类风湿性关节炎的新靶点。PAD4是将蛋白质多肽链中的精氨酸催化成瓜氨酸的修饰酶之一。研究表明(ZhangY.2013)类风湿性关节炎患者体内PAD4蛋白显著表达，使RA患者体内多种蛋白发生瓜氨酸化，例如滑膜中纤维蛋白和抗凝血酶的瓜氨酸化。进而形成瓜氨酸化蛋白/多肽抗原表位(citrullinatedprotein/peptideantigen，CPA)，刺激RA患者自我免疫形成抗瓜氨酸化蛋白抗体。抗瓜氨酸化蛋白抗体视多种蛋白和多肽为目标，在自身免疫性关节炎中有致病作用。PAD4是钙离子依赖性酶，含有5个Ca2+结合位点，由663个氨基酸残基组成，分子量为74kDa。PAD4具有2个结构域，N-结构域和C-结构域。PAD4的催化活性位点位于C-结构域，包含四个关键氨基酸残基Asp350、His471、Asp473和Cys645。研究表明(AritaK.，2004)Ca2+的结合引起PAD4构象的改变，从而形成活性位点裂隙，该裂隙可容纳组蛋白N-末端肽和2个Ca2+结合位点。PAD4可催化单甲基精氨酸残基和肽酰基精氨酸脱亚氨转化为瓜氨酸，不能转化二甲基精氨酸。
目前靶向PAD4抑制剂开发均是针对活性催化位点，分为不可逆类抑制剂和可逆类抑制剂。不可逆类抑制剂主要是卤脒类，包括氟脒(F-amidine)和卤脒(Cl-amidine)，IC50为1.9～22μM。而氢脒类抑制剂是PAD4的可逆性抑制剂，说明PAD4活性位点需要吸电子离去基团(卤素)与硫醇反应，从而增加脒基碳原子的亲电性。现有的可逆性抑制剂(紫杉醇、链霉素、米诺环素等)，除GSK199和GSK484以外(IC50为200nM和50nM)(Lewis，H.D.，2015)，抑制活性均较弱，IC50值在毫摩尔级别。
发明内容
本发明的目的是提供化合物NSC299189以及结合PAD4蛋白的应用。
本发明提供了一种结构式如下的化合物：
上述化合物是萘醌类化合物，并且含有一个2-[2-(2-羟基乙氨基)乙氨基]取代基。
本发明提供了上述化合物与PAD4结合的用途。
上述化合物的羟基与PAD4的活性口袋内Asp473和His471残基形成两个氢键。上述化合物的氨基与PAD4活性口袋内Asp350形成氢键。上述化合物的萘醌基团伸向溶剂化区域，与PAD4活性口袋内Arg374和Arg345残基形成两个氢键。
实验表明，以上化合物可与PAD4蛋白结合，解离常数为KD＝218μM，可以用于发展抗RA的抑制剂。
附图说明
附图是NSC299189的结构图。
具体实施方式
为了理解本发明，下面以实施例进一步说明本发明，但不意于限制本发明的保护范围。
NSC299189化合物(2-[2-(2-羟基乙氨基)乙氨基]萘醌)(2-[2-(2-hydroxyethylamino)ethylamino]naphthalene-1，4-dione)来自于NCI数据库。本发明通过基于氟脒和PAD4反应的过渡态结构进行分子动力学模拟、药效团模型、分子对接和体外化合物筛选，发现了新结构类型的PAD4蛋白抑制剂NSC299189。NSC299189化合物的结构如下所示：
NSC299189的分子式：C14H16N2O3。
NSC299189的分子量：260。
NSC299189是萘醌类化合物，并且含有一个2-[2-(2-羟基乙氨基)乙氨基]取代基。
NSC299189化合物通过与PAD4活性位点结合从而阻止其发挥转化精氨酸为瓜氨酸的活性。
NSC299189化合物与PAD4的解离常数KD＝112μM，有进一步优化成抗RA候选药物的潜力。
NSC299189结合PAD4蛋白的能力是通过自身的分子结构特点决定的。NSC299189结构中的羟基与PAD4的活性口袋内Asp473和His471残基形成两个氢键。氨基与PAD4活性口袋内Asp350形成氢键。并且该化合物的萘醌基团伸向溶剂化区域，与PAD4活性口袋内Arg374和Arg345残基形成两个氢键。从而加强了化合物NSC299189与PAD4蛋白的亲和力。
在抗PAD4蛋白生物活性评估中，由于我们没有直接的PAD4活性检测方法，所以我们运用了表面等离子共振(SurfacePlasmonResonance，SPR)技术，检测了化合物和PAD4蛋白间的结合活性。
1.试验材料
BiacoreT200光学生物传感器(BiacoreLifeSciences，GEHealthcare)CM5生物传感芯片
10mM醋酸钠(pH5.0)
缓冲液：50mmHEPES，pH8.0，300mMNaCl，2mMDTT，20mMCaCl2，和5％DMSO。
2.试验方法
2.1药物配制
药物：---(DMSO储存液，10mM)
含有5％DMSO的HEPES缓冲液做2倍浓度梯度稀释。试验药物终浓度为500μM，250μM，62.5μM，31.25μM，15.63μM，7.81μM。体系中DMSO终浓度为5％。
2.2试验程序
2.2.1用10mM的醋酸钠(pH5.0)将PAD4蛋白稀释成浓度为50μg/ml，采用氨基偶联方式将稀释后的PAD4固定到CM5生物传感芯片上。
2.2.2每个浓度(7.81～500μM)的化合物以30μL/min的恒定流速，注射到PAD4蛋白表面，注射时间为60s。
2.2.3缓冲液(50mmHEPES，pH8.0，300mMNaCl，2mMDTT，20mMCaCl2，和5％DMSO)持续冲洗芯片表面300s，解离化合物。
2.2.4选取31.25μM浓度做重复实验。
2.2.5收集实验数据，并用BiacoreT200评估软件进行数据分析，计算得出化合物和PAD4的解离常数KD值。

Claims (6)

1.一种结构式如下的化合物：
2.根据权利要求1所述的化合物，其特征在于，所述化合物是萘醌类化合物，并且含有一个2-[2-(2-羟基乙氨基)乙氨基]取代基。
3.根据权利要求1所述的化合物的结合PAD4蛋白的用途。
4.根据权利要求3所述的用途，其特征在于，所述化合物的羟基与PAD4的活性口袋内Asp473和His471残基形成两个氢键。
5.根据权利要求3所述的用途，其特征在于，所述化合物的氨基与PAD4活性口袋内Asp350形成氢键。
6.根据权利要求3所述的用途，其特征在于，所述化合物的萘醌基团伸向溶剂化区域，与PAD4活性口袋内Arg374和Arg345残基形成两个氢键。
CN201610116096.7A 2016-03-01 2016-03-01 精氨酸脱亚氨酶4的新型抑制剂 Pending CN105820058A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610116096.7A CN105820058A (zh) 2016-03-01 2016-03-01 精氨酸脱亚氨酶4的新型抑制剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610116096.7A CN105820058A (zh) 2016-03-01 2016-03-01 精氨酸脱亚氨酶4的新型抑制剂

Publications (1)

Publication Number Publication Date
CN105820058A true CN105820058A (zh) 2016-08-03

Family

ID=56987422

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610116096.7A Pending CN105820058A (zh) 2016-03-01 2016-03-01 精氨酸脱亚氨酶4的新型抑制剂

Country Status (1)

Country Link
CN (1) CN105820058A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049296A1 (en) * 2016-09-12 2018-03-15 Padlock Therapeutics, Inc. Heteroaryl inhibitors of pad4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STRUCTURAL MODIFICATION STUDY OF BIS(SUBSTITUTED AMINOALKY1AMINO: "Structural Modification Study of Bis(substituted aminoalky1amino)anthraquinones. An Evaluation of the Relationship of the [2-[ (2-Hydroxyethyl)amino]ethyl]amino Side Chain with Antineoplastic Activity", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049296A1 (en) * 2016-09-12 2018-03-15 Padlock Therapeutics, Inc. Heteroaryl inhibitors of pad4
CN110248934A (zh) * 2016-09-12 2019-09-17 帕德罗科治疗公司 杂芳基pad4抑制剂
US11026937B2 (en) 2016-09-12 2021-06-08 Padlock Therapeutics, Inc. Heteroaryl inhibitors of PAD4
CN110248934B (zh) * 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂

Similar Documents

Publication Publication Date Title
Krishnan et al. The impact of the nitric oxide (NO)/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective
Mio et al. Inhibitors of the hyaluronidases
Teo et al. Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening
Villar-Briones et al. Organic and peptidyl constituents of snake venoms: The picture is vastly more complex than we imagined
Schinner et al. Cyclic nucleotide signalling in kidney fibrosis
Ahmed et al. Potency of Bone Marrow‐Derived Mesenchymal Stem Cells and Indomethacin in Complete Freund’s Adjuvant‐Induced Arthritic Rats: Roles of TNF‐α, IL‐10, iNOS, MMP‐9, and TGF‐β1
Kim et al. Pediatric psoriasis: From new insights into pathogenesis to updates on treatment
Li et al. Histone deacetylases as epigenetic targets for treating Parkinson’s disease
Ma et al. Exercise therapy augments the ischemia-induced proangiogenic state and results in sustained improvement after stroke
Shnayder et al. Prospects for the personalized multimodal therapy approach to pain management via action on NO and NOS
CA3084801A1 (en) Method and composition for treating arginase 1 deficiency
Barzegar et al. The role of the ACE2/MasR axis in ischemic stroke: New insights for therapy
Onuoha et al. Rational design of antirheumatic prodrugs specific for sites of inflammation
Wysocka et al. Matrix metalloproteinases in cardioembolic stroke: from background to complications
Chi et al. Leucine reduced blood–brain barrier disruption and infarct size in early cerebral ischemia-reperfusion
Jia et al. Structure–Activity Relationship of PAD4 Inhibitors and Their Role in Tumor Immunotherapy
Gumpena et al. Glu121‐Lys319 salt bridge between catalytic and N‐terminal domains is pivotal for the activity and stability of Escherichia coli aminopeptidase N
CN112402402A (zh) 一种黄腐酚在制备新型冠状病毒抑制剂中的应用
Lundt et al. Potential therapeutic interventions targeting NAD+ metabolism for ALS
CN105820058A (zh) 精氨酸脱亚氨酶4的新型抑制剂
Göttle et al. Bacillus anthracis edema factor substrate specificity: evidence for new modes of action
Gozzo et al. Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation
Mann et al. Small Molecule Screen Identifies Non-catalytic USP3 Chemical Handle
Lozinski et al. Upregulation of the Renin–Angiotensin System Is Associated with Patient Survival and the Tumour Microenvironment in Glioblastoma
Tolmacheva et al. Catalase activity of IgGs of patients infected with SARS-CoV-2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160803